pancreatic adenocarcinoma
Pancreatic adenocarcinoma is the fifth leading cause of cancer death with a 5-year survival rate of less than 5%.
Molecular biology
Although the role of a few known oncogenes and tumor suppressor genes in the development of pancreatic cancer is fairly well established, it is obvious that the majority of genetic changes responsible for the initiation and progression of this disease are still unknown.
genic inactivations by somatic mutations
- p53 (TP53) at 17p13.1 (MIM.191170)
- p16 (CDKN2A or MTS1) at 9p21 (MIM.600160)
- MADH4 (DPC4 or SMAD4) at 18q21.1 (MIM.600993)
- ACVR1B at 12q13 (MIM.601300)
genic activation
- K-RAS (KRAS2) at 12q12.1 (MIM.190070)
Links
Nomenclature for Classification of Duct Lesions in the Pancreas (NCI, 1999) at Hopkins
Videos
Pancreatic adenocarcinoma by Washington Deceit (1)
Pancreatic adenocarcinoma by Washington Deceit (2)
References
Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med. 2007 Aug;7(5):504-21. PMID: #17691965#
Karhu R, Mahlamaki E, Kallioniemi A. Pancreatic adenocarcinoma — genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer. 2006 Aug;45(8):721-30. PMID: #16688744#
Soto JL, Barbera VM, Saceda M, Carrato A. Molecular biology of exocrine pancreatic cancer. Clin Transl Oncol. 2006 May;8(5):306-12. PMID: #16760004#
Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 2005 Jun;5(6):459-67. PMID: #15905855#
Lynch HT, Deters CA, Lynch JF, Brand RE. Familial pancreatic carcinoma in Jews. Fam Cancer. 2004;3(3-4):233-40. PMID: #15516847#
Hilgers W, Rosty C, Hahn SA. Molecular pathogenesis of pancreatic cancer. Hematol Oncol Clin North Am. 2002 Feb;16(1):17-35, v. PMID: #12063826#
Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002 Dec;2(12):897-909. PMID: #12459728#